Dr Layton joined the University of Waterloo in 2018. Before then, she held the position of the Robert R. and Katherine B. Penn Professor of Mathematics, and Professor of Biomedical Engineering and Medicine at Duke University. She is the Deputy Editor of the American Journal of Physiology–Renal Physiology, Associate Editor of SIAM Review Book Section, and Associate Editor of the SIAM Journal on Applied Dynamical Systems. She also serves as the Associate Dean, Research and International, for the Faculty of Mathematics, and chairs the Research Equity, Diversity and Inclusion Council at the University of Waterloo.
Anita Layton
From this contributor
Early-detection technique analyzes how children with autism scan faces
Researchers at the University of Waterloo in Ontario, Canada, have developed a new autism detection technique that distinguishes among different eye-gaze patterns to help doctors more quickly and accurately detect autism in children.
Early-detection technique analyzes how children with autism scan faces
By
Anita Layton, Mehrshad Sadria, The Conversation
6 August 2019 | 4 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read